Literature DB >> 26950574

Assessment of Depression, Anxiety, and Quality of Life in Singaporean Patients With Glaucoma.

Nigel C S Lim1, Chara H J Fan, Michael K H Yong, Elizabeth P Y Wong, Leonard W Y Yip.   

Abstract

PURPOSE: To determine the prevalence and risk factors for anxiety disorder and depression among glaucoma patients in Singapore, and to assess the relationship between quality of life (QOL) and depression/anxiety.
METHODS: In this cross-sectional study, glaucoma patients aged 21 and above with a known diagnosis of primary open-angle glaucoma or primary angle-closure glaucoma were recruited from a tertiary care hospital. Patients with other types of glaucoma, and coexisting ocular or psychiatric disorders were excluded.Ophthalmic examination was carried out on all participants, which included best-corrected visual acuity (BCVA), intraocular pressure (IOP), gonioscopy, standard automated perimetry, and optic disc evaluation. Sociodemographic information and treatment histories were also collected.The Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A), and Visual Function Questionnaire (VFQ25) were administered to evaluate for depression, anxiety, and impact on QOL, respectively.
RESULTS: A total of 100 patients were included in this study. The mean age was 67.1±12.0 years (range, 24 to 90 y). The frequency of depression and anxiety among our patients was 30% and 64%, respectively. The mean HAM-D score was 4.37±4.17 (range, 0 to 17), whereas the mean HAM-A score was 2.38±2.80 (range, 0 to 13). The mean VFQ25 score was 78.8±16.0 (range, 42.4 to 97.0). The poorest subscale on the VFQ25 was driving, with a mean score of 42.4±42.6 (range, 0.0 to 100.0).We did not find any significant difference between the presence of depression/anxiety between patients with primary open-angle glaucoma (P=0.263) and primary angle-closure glaucoma (P=0.830). Risk factors for depression included: female sex (P=0.020), higher logMAR BCVA in the worse eye (P=0.004), higher cup-disc ratio (P=0.016), lower MD in the better and worse eye (P=0.022 and 0.001, respectively), and lower mean VFQ25 score (P<0.001). Risk factors for anxiety included: lower MD in the worse eye (P=0.004) and lower mean VFQ25 score (P=0.004). There was also no significant association between the use of topical β-blockers/carbonic anhydrase inhibitors with depression (P=0.793) or anxiety (P=0.282).
CONCLUSIONS: There is a relatively high prevalence of depression (30%) and anxiety disorders (64%) among glaucoma patients in Singapore. Female glaucoma patients are more likely to suffer from depression. Other risk factors for depression include higher cup-disc ratio, higher logMAR BCVA, lower MD, and a lower mean VFQ25 score. Risk factors for anxiety disorder include lower MD and lower mean VFQ25 score. Ophthalmologists could consider use of the VFQ25 as an assessment for impairments in QOL in a glaucoma patient. If a glaucoma patient is at high risk of depression or anxiety disorder, a multidisciplinary management approach involving ophthalmology and psychiatry may be required.

Entities:  

Mesh:

Year:  2016        PMID: 26950574     DOI: 10.1097/IJG.0000000000000393

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  16 in total

1.  Anatomical Evidence for the Neural Connection from the Emotional Brain to Autonomic Innervation in the Anterior Chamber Structures of the Eye.

Authors:  Lin Ma; Fang Yang; Qing Liu; Xu-Tao Zhu; Xin Liu; Sen Jin; Hua-Dong Wang; Lei Pei; Fu-Qiang Xu; Hai-Xia Liu
Journal:  Curr Med Sci       Date:  2022-04-02

2.  Effects of non-pharmacological interventions on anxiety, depression, and sleep quality in patients with postoperative glaucoma: A protocol for systematic review and network meta-analysis.

Authors:  Jiong Liu; Lei Cao; Guang Yang; Runhai Zhou
Journal:  Medicine (Baltimore)       Date:  2021-09-03       Impact factor: 1.817

3.  Melatonin concentrations in serum of primary glaucoma patients.

Authors:  Xiao-Ping Ma; Man-Yi Shen; Guang-Lin Shen; Qiao-Ran Qi; Xing-Huai Sun
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

4.  The association between glaucoma and risk of depression: a nationwide population-based cohort study.

Authors:  Yu-Yen Chen; Yun-Ju Lai; Jen-Pang Wang; Ying-Cheng Shen; Chun-Yuan Wang; Hsin-Hua Chen; Hsiao-Yun Hu; Pesus Chou
Journal:  BMC Ophthalmol       Date:  2018-06-22       Impact factor: 2.209

5.  Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.

Authors:  J Rezapour; S Nickels; A K Schuster; M Michal; T Münzel; P S Wild; I Schmidtmann; K Lackner; A Schulz; N Pfeiffer; M E Beutel
Journal:  BMC Ophthalmol       Date:  2018-06-28       Impact factor: 2.209

6.  Self-rated depression and eye diseases: The Beijing Eye Study.

Authors:  Jost B Jonas; Wen Bin Wei; Liang Xu; Marcella Rietschel; Fabian Streit; Ya Xing Wang
Journal:  PLoS One       Date:  2018-08-10       Impact factor: 3.240

7.  Psychometric properties of the Glaucoma Quality of Life-15 questionnaire: Use of explanatory factor analysis.

Authors:  Hamideh Mahdaviazad; Narges Roustaei; Masoumeh Beigom Masoumpour; Mohammad Reza Razeghinejad
Journal:  J Curr Ophthalmol       Date:  2018-01-17

8.  Influence of painless one-eye blindness on depression, anxiety and quality of life in glaucoma patients with a normal fellow eye.

Authors:  Gábor Holló; Nikolett Gabriella Sándor; Péter Kóthy; Anna Géczy
Journal:  BMC Ophthalmol       Date:  2021-02-17       Impact factor: 2.209

9.  Illness uncertainty, anxiety and depression in Chinese patients with glaucoma or cataract.

Authors:  Dandan Zhang; Zhigang Fan; Xinbo Gao; Wenmin Huang; Qiongman Yang; Zhongwen Li; Mingkai Lin; Huiming Xiao; Jian Ge
Journal:  Sci Rep       Date:  2018-08-03       Impact factor: 4.379

10.  Effect of depressive symptom and depressive disorder on glaucoma incidence in elderly.

Authors:  Younhea Jung; Kyungdo Han; Sheng-Min Wang; Hye Yeon Yoon; Jung Il Moon
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.